What is Imbio?
Imbio is at the forefront of AI-driven medical imaging analysis, focusing on lung and cardiothoracic conditions to enhance personalized medicine. The company develops sophisticated algorithms for detailed lung density and texture analyses, pulmonary hypertension assessments, and coronary calcification analysis. These advanced tools are designed to empower physicians, health systems, and patients with more precise diagnostic capabilities. Imbio also engages in strategic collaborations with medical device and pharmaceutical firms to create bespoke imaging solutions that support targeted disease therapies, offering secure, scalable, and interoperable deployments to improve patient care globally.
How much funding has Imbio raised?
Imbio has raised a total of $2.7M across 3 funding rounds:
Private Equity
$1.1M
Series A
$1.5M
Debt
$150K
Private Equity (2015): $1.1M, investors not publicly disclosed
Series A (2017): $1.5M led by Invenshure
Debt (2020): $150K supported by PPP
Key Investors in Imbio
Invenshure
Invenshure is dedicated to transforming challenging problems into successful companies by leveraging institutional intellectual property. Their early-stage model focuses on delivering returns to investors while contributing positively to society.
What's next for Imbio?
With its recent major strategic investment and substantial overall capital, Imbio is well-positioned for accelerated growth and further innovation in the AI-powered medical diagnostics sector. The company's focus on enhancing personalized medicine through advanced imaging analysis suggests a trajectory towards expanding its product suite and deepening its market penetration. Future developments are likely to involve refining existing algorithms, exploring new diagnostic applications, and strengthening partnerships within the healthcare ecosystem to drive the adoption of its transformative technologies.
See full Imbio company page
